JP2005535688A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2005535688A5 JP2005535688A5 JP2004525354A JP2004525354A JP2005535688A5 JP 2005535688 A5 JP2005535688 A5 JP 2005535688A5 JP 2004525354 A JP2004525354 A JP 2004525354A JP 2004525354 A JP2004525354 A JP 2004525354A JP 2005535688 A5 JP2005535688 A5 JP 2005535688A5
- Authority
- JP
- Japan
- Prior art keywords
- optionally
- alkylamino
- branched
- independently
- linear
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 claims 7
- 230000000259 anti-tumor effect Effects 0.000 claims 5
- 239000003112 inhibitor Substances 0.000 claims 5
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 4
- 125000004432 carbon atom Chemical group C* 0.000 claims 4
- -1 cyano, hydroxyl Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 4
- 150000002367 halogens Chemical class 0.000 claims 4
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 3
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 claims 3
- 201000011510 cancer Diseases 0.000 claims 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 3
- 229920006395 saturated elastomer Polymers 0.000 claims 3
- 125000003837 (C1-C20) alkyl group Chemical group 0.000 claims 2
- 108091000080 Phosphotransferase Proteins 0.000 claims 2
- 108091005682 Receptor kinases Proteins 0.000 claims 2
- 239000000654 additive Substances 0.000 claims 2
- 125000003282 alkyl amino group Chemical group 0.000 claims 2
- 230000001086 cytosolic effect Effects 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- 229940127557 pharmaceutical product Drugs 0.000 claims 2
- 102000020233 phosphotransferase Human genes 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 1
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims 1
- GHASVSINZRGABV-UHFFFAOYSA-N Fluorouracil Chemical compound FC1=CNC(=O)NC1=O GHASVSINZRGABV-UHFFFAOYSA-N 0.000 claims 1
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 229930012538 Paclitaxel Natural products 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 239000000556 agonist Substances 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 239000005557 antagonist Substances 0.000 claims 1
- 230000000340 anti-metabolite Effects 0.000 claims 1
- 229940100197 antimetabolite Drugs 0.000 claims 1
- 239000002256 antimetabolite Substances 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- 229940041181 antineoplastic drug Drugs 0.000 claims 1
- 229960001561 bleomycin Drugs 0.000 claims 1
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 1
- YAYRGNWWLMLWJE-UHFFFAOYSA-L carboplatin Chemical compound O=C1O[Pt](N)(N)OC(=O)C11CCC1 YAYRGNWWLMLWJE-UHFFFAOYSA-L 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 239000012050 conventional carrier Substances 0.000 claims 1
- 229960000684 cytarabine Drugs 0.000 claims 1
- 239000000824 cytostatic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- 229960000390 fludarabine Drugs 0.000 claims 1
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims 1
- 229960002949 fluorouracil Drugs 0.000 claims 1
- 229960005277 gemcitabine Drugs 0.000 claims 1
- SDUQYLNIPVEERB-QPPQHZFASA-N gemcitabine Chemical compound O=C1N=C(N)C=CN1[C@H]1C(F)(F)[C@H](O)[C@@H](CO)O1 SDUQYLNIPVEERB-QPPQHZFASA-N 0.000 claims 1
- 150000002391 heterocyclic compounds Chemical class 0.000 claims 1
- 239000005556 hormone Substances 0.000 claims 1
- 229940088597 hormone Drugs 0.000 claims 1
- HOMGKSMUEGBAAB-UHFFFAOYSA-N ifosfamide Chemical compound ClCCNP1(=O)OCCCN1CCCl HOMGKSMUEGBAAB-UHFFFAOYSA-N 0.000 claims 1
- 229960001101 ifosfamide Drugs 0.000 claims 1
- 229920002521 macromolecule Polymers 0.000 claims 1
- 229960000485 methotrexate Drugs 0.000 claims 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 1
- 229960001756 oxaliplatin Drugs 0.000 claims 1
- 229960001592 paclitaxel Drugs 0.000 claims 1
- 239000008177 pharmaceutical agent Substances 0.000 claims 1
- 230000019491 signal transduction Effects 0.000 claims 1
- 230000011664 signaling Effects 0.000 claims 1
- 125000004079 stearyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 1
- NRUKOCRGYNPUPR-QBPJDGROSA-N teniposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@@H](OC[C@H]4O3)C=3SC=CC=3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 NRUKOCRGYNPUPR-QBPJDGROSA-N 0.000 claims 1
- 229960001278 teniposide Drugs 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US39961502P | 2002-07-30 | 2002-07-30 | |
| PCT/EP2003/008346 WO2004012744A1 (de) | 2002-07-30 | 2003-07-29 | Anwendung von alkylphosphocholinen in kombination mit antitumormedikamenten |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2005535688A JP2005535688A (ja) | 2005-11-24 |
| JP2005535688A5 true JP2005535688A5 (OSRAM) | 2009-08-20 |
Family
ID=31495746
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2004525354A Pending JP2005535688A (ja) | 2002-07-30 | 2003-07-29 | 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用 |
Country Status (26)
| Country | Link |
|---|---|
| US (3) | US8389497B2 (OSRAM) |
| EP (2) | EP1545553B1 (OSRAM) |
| JP (1) | JP2005535688A (OSRAM) |
| KR (3) | KR20110102485A (OSRAM) |
| CN (1) | CN1302780C (OSRAM) |
| AR (1) | AR040717A1 (OSRAM) |
| AT (1) | ATE516036T1 (OSRAM) |
| AU (2) | AU2003253350B2 (OSRAM) |
| BR (1) | BR0313048A (OSRAM) |
| CA (1) | CA2493023C (OSRAM) |
| CY (1) | CY1111902T1 (OSRAM) |
| DK (1) | DK1545553T3 (OSRAM) |
| ES (1) | ES2369535T3 (OSRAM) |
| HR (1) | HRP20050184B1 (OSRAM) |
| IL (1) | IL166329A (OSRAM) |
| MX (1) | MXPA05001203A (OSRAM) |
| NO (1) | NO335196B1 (OSRAM) |
| NZ (1) | NZ538428A (OSRAM) |
| PL (1) | PL375493A1 (OSRAM) |
| PT (1) | PT1545553E (OSRAM) |
| RU (1) | RU2005105693A (OSRAM) |
| SI (1) | SI1545553T1 (OSRAM) |
| TW (1) | TWI332007B (OSRAM) |
| UA (1) | UA82322C2 (OSRAM) |
| WO (1) | WO2004012744A1 (OSRAM) |
| ZA (1) | ZA200500453B (OSRAM) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR20110102485A (ko) | 2002-07-30 | 2011-09-16 | 아에테르나 젠타리스 게엠베하 | 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품 |
| US8383605B2 (en) | 2002-07-30 | 2013-02-26 | Aeterna Zentaris Gmbh | Use of alkylphosphocholines in combination with antimetabolites for the treatment of benign and malignant oncoses in humans and mammals |
| DE10324911B4 (de) | 2003-05-30 | 2005-08-18 | Siemens Ag | Röntgenvorrichtung mit partiellem digitalem Detektor und Verfahren zum Betrieb einer solchen |
| WO2006081452A2 (en) * | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| EP1800684A1 (en) * | 2005-12-20 | 2007-06-27 | Zentaris GmbH | Novel alkyl phospholipid derivatives and uses thereof |
| US20070167408A1 (en) * | 2005-12-19 | 2007-07-19 | Zentaris Gmbh | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| CA2632449A1 (en) * | 2005-12-19 | 2007-06-28 | Aeterna Zentaris Gmbh | Alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| US8703179B2 (en) | 2006-05-11 | 2014-04-22 | Kimberly-Clark Worldwide, Inc. | Mucosal formulation |
| CN101808516B (zh) * | 2007-07-30 | 2013-08-28 | 阿迪生物科学公司 | 作为mek抑制剂的包括多晶型物的n-(芳氨基)磺酰胺衍生物和组合物、其使用方法和制备方法 |
| AU2009324464B2 (en) * | 2008-12-11 | 2016-05-05 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| US8383607B2 (en) | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5942639A (en) * | 1991-07-04 | 1999-08-24 | Asta Medica Aktiengesellschaft | Process for the preparation of alkylphosphocholines and the production thereof in pure form |
| EP0521353B1 (de) * | 1991-07-04 | 1996-04-17 | ASTA Medica Aktiengesellschaft | Arzneimittel mit antineoplastischer Wirkung enthaltend als Wirkstoff Octadecyl-[2-(N-methylpiperidino)-ethyl]-phosphat und Verfahren zu dessen Herstellung |
| US6172050B1 (en) * | 1992-07-11 | 2001-01-09 | Asta Medica Aktiengesellschaft | Phospholipid derivatives |
| JP3079993B2 (ja) * | 1996-03-27 | 2000-08-21 | 日本電気株式会社 | 真空マイクロデバイスおよびその製造方法 |
| DE19650778C2 (de) * | 1996-12-06 | 2001-01-04 | Asta Medica Ag | Verwendung von Dopaminrezeptor-Antagonisten in der palliativen Tumortherapie |
| EP1051159B1 (en) | 1998-01-22 | 2002-04-10 | Zentaris AG | Solid pharmaceutical compositions containing miltefosine for oral administration in the treatment of leishmaniasis |
| WO2000033917A1 (de) * | 1998-12-04 | 2000-06-15 | Max-Delbrück-Centrum für Molekulare Medizin | Mittel zur tumortherapie auf liposomenbasis die tamoxifen enthalten |
| WO2000037088A1 (en) * | 1998-12-21 | 2000-06-29 | Inkeysa.Sa | Use of etherlysophospholipids as antiinflammatory agents |
| LT2762140T (lt) * | 2001-02-19 | 2017-06-26 | Novartis Ag | Solidinių smegenų navikų gydymas rapamicino dariniu |
| US6800639B2 (en) * | 2001-03-23 | 2004-10-05 | Shire Biochem Inc. | Pharmaceutical combination for the treatment of cancer |
| WO2003005522A1 (es) | 2001-07-04 | 2003-01-16 | Acuna Arturo | Tapones para sellado de ductos para redes electricas, telefonicas y de fibra optica. |
| EP1461083B1 (en) * | 2002-01-02 | 2006-03-29 | Pharmacia Italia S.p.A. | Combined therapy against tumors comprising substituted acryloyl distamycin derivatives and protein kinase (serine/threonine kinase) inhibitors |
| KR20110102485A (ko) | 2002-07-30 | 2011-09-16 | 아에테르나 젠타리스 게엠베하 | 항종양 약제와 조합하여 사용하기 위한 알킬포스포콜린의 약물 제품 |
| WO2005000318A2 (en) * | 2003-06-23 | 2005-01-06 | Neopharm, Inc. | Method of inducing apoptosis and inhibiting cardiolipin synthesis |
| WO2006081452A2 (en) | 2005-01-28 | 2006-08-03 | Robert Birch | Co-administration of perifosine with chemotherapeutics |
| US20070167408A1 (en) * | 2005-12-19 | 2007-07-19 | Zentaris Gmbh | Novel alkyl phospholipid derivatives with reduced cytotoxicity and uses thereof |
| US8383607B2 (en) * | 2010-03-31 | 2013-02-26 | Aeterna Zentaris Gmbh | Perifosine and capecitabine as a combined treatment for cancer |
-
2003
- 2003-07-29 KR KR1020117017914A patent/KR20110102485A/ko not_active Ceased
- 2003-07-29 KR KR1020127034433A patent/KR20130016413A/ko not_active Ceased
- 2003-07-29 HR HRP20050184AA patent/HRP20050184B1/hr not_active IP Right Cessation
- 2003-07-29 PT PT03766336T patent/PT1545553E/pt unknown
- 2003-07-29 MX MXPA05001203A patent/MXPA05001203A/es active IP Right Grant
- 2003-07-29 AR AR20030102710A patent/AR040717A1/es unknown
- 2003-07-29 EP EP03766336A patent/EP1545553B1/de not_active Expired - Lifetime
- 2003-07-29 JP JP2004525354A patent/JP2005535688A/ja active Pending
- 2003-07-29 BR BR0313048-7A patent/BR0313048A/pt not_active IP Right Cessation
- 2003-07-29 TW TW092120705A patent/TWI332007B/zh not_active IP Right Cessation
- 2003-07-29 RU RU2005105693/15A patent/RU2005105693A/ru unknown
- 2003-07-29 SI SI200332027T patent/SI1545553T1/sl unknown
- 2003-07-29 ES ES03766336T patent/ES2369535T3/es not_active Expired - Lifetime
- 2003-07-29 EP EP10010451A patent/EP2301551A1/de not_active Withdrawn
- 2003-07-29 UA UAA200500510A patent/UA82322C2/uk unknown
- 2003-07-29 CA CA2493023A patent/CA2493023C/en not_active Expired - Lifetime
- 2003-07-29 PL PL03375493A patent/PL375493A1/xx unknown
- 2003-07-29 AU AU2003253350A patent/AU2003253350B2/en not_active Ceased
- 2003-07-29 WO PCT/EP2003/008346 patent/WO2004012744A1/de not_active Ceased
- 2003-07-29 CN CNB038181010A patent/CN1302780C/zh not_active Expired - Fee Related
- 2003-07-29 DK DK03766336.6T patent/DK1545553T3/da active
- 2003-07-29 AT AT03766336T patent/ATE516036T1/de active
- 2003-07-29 KR KR1020057001510A patent/KR101066804B1/ko not_active Expired - Lifetime
- 2003-07-29 NZ NZ538428A patent/NZ538428A/en not_active IP Right Cessation
- 2003-07-30 US US10/632,187 patent/US8389497B2/en not_active Expired - Fee Related
-
2005
- 2005-01-17 IL IL166329A patent/IL166329A/en not_active IP Right Cessation
- 2005-01-18 ZA ZA2005/00453A patent/ZA200500453B/en unknown
- 2005-02-25 NO NO20051040A patent/NO335196B1/no not_active IP Right Cessation
-
2008
- 2008-07-10 AU AU2008203060A patent/AU2008203060B2/en not_active Ceased
-
2010
- 2010-03-31 US US12/751,454 patent/US8551977B2/en not_active Expired - Fee Related
- 2010-03-31 US US12/751,608 patent/US8507710B2/en not_active Expired - Fee Related
-
2011
- 2011-09-30 CY CY20111100944T patent/CY1111902T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP5579715B2 (ja) | ｃｄｋ阻害剤および抗悪性腫瘍剤を含む治療用組合せ | |
| JP2005535688A5 (OSRAM) | ||
| CN107864625B (zh) | 含有取代的2,3-二氢咪唑并[1,2-c]喹唑啉的组合产品 | |
| HRP20100563T1 (hr) | Derivati dihidropirazolopirimidinona | |
| KR900002784A (ko) | 항종양치료에 사용하기 위한 약제학적 결합제제 | |
| CA2440160C (en) | Antitumor compositions containing taxane derivatives | |
| TW200635923A (en) | Tricyclic heterocycles, their manufacture and use as pharmaceutical agents | |
| RU2006146619A (ru) | Лечение гемцитабином и ингибитором рецептора эпидермального фактора роста(egfr) | |
| JP2019501197A5 (ja) | 腫瘍を処置するための抗ｈｅｒ２組み合わせ | |
| JP2012523435A5 (OSRAM) | ||
| RU2010117635A (ru) | Комбинированная химиотерапия | |
| WO2010136394A1 (en) | Therapeutic combination comprising a plk1 inhibitor and an antineoplastic agent | |
| Morgenstern et al. | Phase I study of vinblastine and sirolimus in pediatric patients with recurrent or refractory solid tumors | |
| WO2024211712A9 (en) | Macrocyclic ras inhibitors | |
| JP2019506392A5 (OSRAM) | ||
| JP2020520923A5 (OSRAM) | ||
| Chrom et al. | Second-line treatment of advanced gastric cancer: current options and future perspectives | |
| JP2005535688A (ja) | 抗腫瘍医薬との組合せにおけるアルキルホスホコリンの使用 | |
| Cresta et al. | Phase I study of bortezomib with weekly paclitaxel in patients with advanced solid tumours | |
| JP6461088B2 (ja) | 高分子化カンプトテシン誘導体及び高分子化ｈｓｐ９０阻害剤誘導体を含む医薬組成物 | |
| To et al. | Synergistic interaction between platinum-based antitumor agents and demethylcantharidin | |
| Cheson | New agents in follicular lymphoma | |
| RU2007119776A (ru) | Новые аминопиридиновые производные, обладающие селективной aurora a ингибирующей активностью | |
| JP2003526659A (ja) | 癌の治療のためのカンプトテシンもしくはカンプトテシン誘導体およびアルキル化剤を含んで成る組成物 | |
| WO2012075210A2 (en) | Method for treating refractory cancer |